Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Koji Shindo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-6797-0289; OpenAlex author ID A5067498947, A5086787507. Sources: OpenAlex.

Their work

Papers
30 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
96
Papers, trials and grants by year

2012: 1 paper · 2013: 5 papers · 2014: 1 paper · 2015: 3 papers · 2016: 1 paper · 2017: 4 papers · 2018: 1 paper · 2019: 2 papers · 2020: 4 papers · 2021: 3 papers · 2022: 1 paper · 2023: none · 2024: 3 papers · 2025: 1 paper

Papers 30

  1. Prognostic Significance of Desmoplastic Reaction Classification and Its Association With Stromal Biomarkers in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.modpat.2025.100865↗
  2. TAK1 Promotes an Immunosuppressive Tumor Microenvironment through Cancer-Associated Fibroblast Phenotypic Conversion in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1158/1078-0432.ccr-24-1004↗
  3. Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03178-6↗
  4. Dynamic glycolytic reprogramming effects on dendritic cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03192-8↗
  5. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses. Co-author DOI 10.1186/s13046-022-02301-9↗
  6. FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience. Co-author DOI 10.1007/s00595-020-02123-2↗
  7. Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2021.04.013↗
  8. New high-throughput screening detects compounds that suppress pancreatic stellate cell activation and attenuate pancreatic cancer growth. Co-author DOI 10.1016/j.pan.2021.04.002↗
  9. Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. Co-author DOI 10.1016/j.jmoldx.2020.02.010↗
  10. Concomitant Intraductal Papillary Mucinous Neoplasm in Pancreatic Ductal Adenocarcinoma Is an Independent Predictive Factor for the Occurrence of New Cancer in… Co-author DOI 10.1097/sla.0000000000003060↗
  11. Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5. Co-author DOI 10.1371/journal.pone.0228015↗
  12. Neutrophil extracellular traps promote liver micrometastasis in pancreatic ductal adenocarcinoma via the activation of cancer‑associated fibroblasts. Co-author DOI 10.3892/ijo.2019.4951↗
  13. CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis. Co-author DOI 10.1007/s00432-019-02860-z↗
  14. Cancer-associated acinar-to-ductal metaplasia within the invasive front of pancreatic cancer contributes to local invasion. Co-author DOI 10.1016/j.canlet.2018.12.005↗
  15. Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Co-author DOI 10.1073/pnas.1720588115↗
  16. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cance… Co-author DOI 10.1136/gutjnl-2015-311166↗
  17. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.2017.72.3502↗
  18. Lack of association between the pancreatitis risk allele CEL-HYB and pancreatic cancer. Co-author DOI 10.18632/oncotarget.15137↗
  19. IL2RG, identified as overexpressed by RNA-seq profiling of pancreatic intraepithelial neoplasia, mediates pancreatic cancer growth. Co-author DOI 10.18632/oncotarget.19848↗
  20. Obstructive Sleep Apnea and Pathological Characteristics of Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1371/journal.pone.0164195↗
  21. Anterior gradient 2 downregulation in a subset of pancreatic ductal adenocarcinoma is a prognostic factor indicative of epithelial-mesenchymal transition. Co-author DOI 10.1038/labinvest.2014.138↗
  22. TM4SF1 as a prognostic marker of pancreatic ductal adenocarcinoma is involved in migration and invasion of cancer cells. Co-author DOI 10.3892/ijo.2015.3022↗
  23. Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer. Co-author DOI 10.3892/or.2015.4138↗
  24. CD166/ALCAM expression is characteristic of tumorigenicity and invasive and migratory activities of pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0107247↗
  25. MAL2 expression predicts distant metastasis and short survival in pancreatic cancer. Co-author DOI 10.1016/j.surg.2013.03.010↗
  26. Kindlin-2 expression in peritumoral stroma is associated with poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e318279bd66↗
  27. Migratory activity of CD105+ pancreatic cancer cells is strongly enhanced by pancreatic stellate cells. Co-author DOI 10.1097/mpa.0b013e318293e7bd↗
  28. Kindlin-1 expression is involved in migration and invasion of pancreatic cancer. Co-author DOI 10.3892/ijo.2013.1838↗
  29. Unresectable pancreatic ductal adenocarcinoma in the remnant pancreas diagnosed during every-6-month surveillance after resection of branch duct intraductal pa… Co-author DOI 10.6092/1590-8577/1494↗
  30. CD271⁺ subpopulation of pancreatic stellate cells correlates with prognosis of pancreatic cancer and is regulated by interaction with cancer cells. Co-author DOI 10.1371/journal.pone.0052682↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenoki Ohuchida · 19 shared papers, 2012–2024 · strength 1.65
  2. Kohei Nakata · 12 shared papers, 2019–2025 · strength 1.59
  3. Yoshinao Oda · 14 shared papers, 2013–2025 · strength 1.48
  4. Naoki Ikenaga · 12 shared papers, 2012–2024 · strength 1.18
  5. Masafumi Nakamura · 10 shared papers, 2015–2024 · strength 1.07
  6. Chika Iwamoto · 9 shared papers, 2019–2024 · strength 1.04
  7. Takao Ohtsuka · 16 shared papers, 2012–2021 · strength 0.98
  8. Toshiya Abe · 6 shared papers, 2018–2024 · strength 0.61
  9. Yoshihiro Miyasaka · 7 shared papers, 2015–2021 · strength 0.58
  10. Tomohiko Shinkawa · 4 shared papers, 2020–2024 · strength 0.52
  11. Michael Goggins · 7 shared papers, 2016–2020 · strength 0.43
  12. Ralph H. Hruban MD · 7 shared papers, 2016–2020 · strength 0.43
  13. Masafumi Nakamura · 2 shared papers, 2024–2025 · strength 0.40
  14. Nan Sheng · 2 shared papers, 2024 · strength 0.38
  15. Masao Tanaka · 10 shared papers, 2012–2015 · strength 0.38
  16. Jun Yu · 6 shared papers, 2017–2020 · strength 0.38
  17. Yohei Ando · 4 shared papers, 2019–2021 · strength 0.36
  18. Chikanori Tsutsumi · 2 shared papers, 2024 · strength 0.35
  19. Koki Oyama · 2 shared papers, 2024 · strength 0.35
  20. Shin Takesue · 4 shared papers, 2019–2020 · strength 0.33
  21. Noboru Ideno · 3 shared papers, 2013–2024 · strength 0.33
  22. Yuki Mochida · 2 shared papers, 2022–2024 · strength 0.32
  23. Masaya Suenaga · 5 shared papers, 2017–2020 · strength 0.31
  24. Christopher Lee Wolfgang · 5 shared papers, 2016–2020 · strength 0.30
  25. Akiko Sagara · 3 shared papers, 2020–2021 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.